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COMPARATIVE COST OF ABLATION IN ATRIAL FIBRILLATION 
PATIENTS STRATIFIED BY PROCEDURAL SUCCESS VERSUS FAILURE: 
IMPLICATIONS FOR RESOURCE UTILIZATION IN MEDICARE-AGED 
ABLATION CANDIDATES IN THE UNITED STATES
Kim MH1, Lin J2, Foltz Boklage SH3, Kreilick CA3
1Northwestern University, Chicago, IL, USA, 2sanoﬁ-aventis U.S., Bridgewater, NJ, USA, 
3ProUnlimited, Boca Raton, FL, USA
OBJECTIVES: Catheter ablation is increasingly used to maintain sinus rhythm in 
atrial ﬁbrillation (AF) patients unresponsive to antiarrhythmic drugs (AADs). We 
compared medical costs in Medicare-aged AF patients following successful vs unsuc-
cessful ablation. METHODS: In this retrospective study, AF pts with 1) an index 
ablation; 2) ≥12 months’ medical/pharmacy coverage pre- and post-index; 3) ≥2 AF 
inpatient/outpatient visits within 6 months and AAD treatment within 12 months of 
index ablation were identiﬁed from the MarketScan® Medicare database (January 
2002-June 2007). Ablation success was deﬁned as absence of AAD treatment 6–12 
months post ablation. RESULTS: A total of 135 AF patients (67% men, mean 73 yrs) 
were included; ablation was successful in 69 and failed in 66 patients. Most patients 
(97% with successful vs 94% with failed ablation) underwent only 1 ablation proce-
dure during the 12-month study. After successful ablation, patients discontinued AAD 
in (mean) 54 days. Use of rate-control and anticoagulant drugs declined after success-
ful ablation (67% vs. 87% and 64% vs. 86% patients, respectively), but remained 
largely undiminished after failed ablation (70% vs. 74% and 82% vs. 88% patients, 
respectively). Mean (median) per-patient costs per ablation were $13,655 ($11,795) 
for successful vs. $17,294 ($11,778) for failed ablation. Other AF-related costs over 
1 yr post index ablation were $2394 ($7677) for successful vs. $2703 ($4478) for 
failed ablation patients. Overall annual per-patient costs were lower in patients with 
successful (mean $16,049; median $17,135) vs. failed ($19,997; $26,635) ablation (P 
= 0.07). CONCLUSIONS: Ablation failed in half of ‘real-world’ Medicare-aged AF 
patients, and few underwent repeat ablation. Overall costs were higher for failed vs 
successful ablation patients, possibly because of differences in AF-related issues, com-
plications, and ablation methods. Over time, this cost differential would likely increase 
if failed ablation patients underwent repeat procedures. Identiﬁcation of predictors for 
ablation success may reduce medical costs.
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RISK-BENEFIT FRAMEWORK FOR EVALUATION OF GENE EXPRESSION 
PROFILING IN WOMEN WITH EARLY STAGE BREAST CANCER: A 
DECISION MODEL DEVELOPED IN COLLABORATION WITH 
STAKEHOLDERS
Roth J, Veenstra D
University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, 
WA, USA
OBJECTIVES: To develop a parsimonious risk-beneﬁt model to assist stakeholders in 
evaluating gene expression proﬁling (GEP) to guide use of adjuvant chemotherapy in 
early stage breast cancer compared to clinical guidelines. METHODS: A decision 
model was developed to estimate comparative beneﬁts and harms of using GEP relative 
to NCCN guidelines, including disease recurrences, adverse events, life years, and 
quality-adjusted life years (QALYs). Model structure and output were developed 
through a collaborative feedback process with stakeholders. The model’s interactive 
structure allows users to specify the GEP, adjuvant chemotherapy regimen, and prog-
nostic and predictive risk stratiﬁcation. A Markov process was utilized to estimate 
clinical outcomes, and parameter uncertainty was evaluated through one-way and 
probabilistic sensitivity analysis. The base case patient was a pre-menopausal woman 
of age 44. The prognostic and predictive properties of the GEPs were derived from 
published retrospective analyses of RCTs. Adjuvant chemotherapy regimen-speciﬁc 
utility decrements were incorporated based on trial-based adverse event rates. 
RESULTS: Preliminary analyses indicate that a GEP that provides prognostic informa-
tion only would identify 61% of women to receive adjuvant chemotherapy, while 
96% would be identiﬁed by clinical guidelines. Based on these estimates, GEP and 
clinical guidelines would prevent 29% and 34% of distant recurrences, respectively. 
These ﬁndings suggest that GEP may lead to a net harm, with 9.86 QALYs for GEP 
versus 10.08 for clinical guidelines, due to increased risk of disease recurrence, despite 
the avoidance of chemotherapy and side effects in 39% of women. Analyses of other 
risk stratiﬁcation approaches are ongoing. CONCLUSIONS: We found that use of 
GEP to guide use of adjuvant chemotherapy in early stage breast cancer could lead to 
a decrease in QALYs relative to the use of clinical guidelines if chemotherapy predic-
tive information is not available. Ongoing efforts are focused on collaboration with 
stakeholders to align model structure and output with stakeholder needs.
PM2
EFFECTS OF PRIMARY PROPHYLACTIC G-CSF USE AND DURATION OF 
USE ON NEUTROPENIA HOSPITALIZATIONS FOR ELDERLY BREAST 
CANCER PATIENTS RECEIVING CHEMOTHERAPY
Rajan SS1, Lyman G2
1University of Houston, Houston, TX, USA, 2Duke University, Durham, NC, USA
OBJECTIVES: Systemic chemotherapy is a vital component of breast cancer manage-
ment. However early-onset chemotherapy-toxicities like neutropenia hinder chemo-
therapy use in breast cancer patients, especially in the elderly. Depending on the 
severity, neutropenia management requires hospitalization and aggressive systemic 
antibiotic administration, and involves reduction or discontinuation of chemotherapy. 
Primary prophylactic granulocyte-colony stimulating factors (PPG-CSF), especially 
when administered over adequate duration, help prevent neutropenia. Nevertheless, 
evidence supporting the effectiveness of PPG-CSF in the elderly is limited, and thus 
the ASCO guidelines for PPG-CSF use and speciﬁcations for duration of its use in the 
elderly are not explicit. This study analyzed the effects of PPG-CSF and adequate 
duration of PPG-CSF on the occurrence of chemotherapy-induced neutropenia hospi-
talizations in elderly breast cancer patients. METHODS: A retrospective observational 
study for patients newly diagnosed with primary breast cancer between the years 1994 
to 2002 using the SEER-Medicare data was performed. To account for the non-ran-
dom nature of the observational data a non-parametric covariate genetic matching 
technique was used to pre-process the data before performing logistic regressions to 
estimate the treatment effects. RESULTS: Administration of PPG-CSF during the ﬁrst 
course of chemotherapy reduced neutropenia hospitalizations by 15% within the ﬁrst 
three months and 16% within the ﬁrst six months of chemotherapy initiation (p < 
0.05). Hospitalizations within the ﬁrst three months of chemotherapy initiation were 
three times higher in women receiving less than ﬁve consecutive days of PPG-CSF 
compared to women receiving PPG-CSF for ﬁve of more days (p < 0.05). Hospitaliza-
tions within the ﬁrst one and six months were also considerably lower with longer 
PPG-CSF duration (≥5days) (p < 0.10). CONCLUSIONS: PPG-CSF use is associated 
with reduction in occurrence of severe neutropenia and reduced in-patient health care 
utilization. These ﬁndings have implications for ASCO guidelines and Medicare cover-
age policies for PPG-CSF administration and duration of administration in elderly 
breast cancer patients.
PM3
ECONOMIC EVALUATION OF GENETIC TEST IN COMBINATION WITH 
PREVENTIVE DONEPEZIL TREATMENT FOR AMNESTIC MILD 
COGNITIVE IMPAIRMENT PATIENTS: LIFE- TIME MODEL
Djalalov S1, Yong J1, Saposnik G1, Musa Z2, Mendelson M3, Siminovitch K4, Black S5, 
Hoch J2
1St. Michael’s Hospital, Toronto, ON, Canada, 2Cancer Care Ontario, Toronto, ON, Canada, 
3Caledon Institute of Social Policy, Ottawa, ON, Canada, 4Mount Sinai Hospital, Toronto, 
ON, Canada, 5Sunnybrook Health Sciences Centre, Toronto, ON, Canada
OBJECTIVES: Amnestic Mild Cognitive Impairment (AMCI) patients with Apolipo-
protein e4 alleles (APOEe4), a type of genetic mutation, have higher rates of progres-
sion to Alzheimer Disease (AD) than patients without this genetic mutation. Some 
studies suggest that early diagnoses and treatment in APOE e4 carriers will delay their 
progression to AD.Objective is to evaluate the cost-effectiveness of APOEe4 testing in 
combination with preventive Donepezil treatment in AMCI patients in Canada. 
METHODS: We performed a cost-effectiveness analysis using a Markov model based 
on a formal literature review. The base case was assumed to be a 70-year-old AMCI 
individual with problems in the memory domain. The model used a societal perspec-
tive and a time horizon of 30 years. Two strategies were evaluated: genetic testing and 
preventive Donepezil treatment for APOEe4 gene carriers vs. no testing (the current 
standard of care in Canada). Outcome measures were quality-adjusted life years 
(QALYs), lifetime costs, and the incremental cost-effectiveness ratio (ICER). RESULTS: 
The genetic testing and Donepezil treatment combination strategy resulted in the gain 
of 0.047 QALYs, when compared to not testing. The Incremental cost was CAD $ 
1010 with Donepezil treatment; consequently, the ICER for the base case is estimated 
to be $ 21,586. The prevalence of genetic mutations, cost of genetic test and cost of 
Alzheimer disease had a small effect on the cost-effectiveness results; however, the 
ICER is sensitive to AMCI utility, rate of progression to AD, AMCI surveillance cost, 
efﬁcacy and cost of Donepezil preventive treatment. We conducted a sub-analysis by 
sex, and found that the ICER was lower for females than for males. CONCLUSIONS: 
Genetic testing in combination with preventive donepezil treatment for AMCI patients 
may be economically attractive in the current setting. Our preliminary ﬁndings are 
limited by substantial uncertainties surrounding the long-term efﬁcacy of Donepezil 
preventive treatment and the rate of progression to AD.
PM4
TRANSLATIONAL AND POLICY RESEARCH IN PERSONALIZED 
MEDICINE FOR CANCER
Marshall DA1, Kulin NA1, Elkin EB2, Ferrusi IL1, Phillips K3
1McMaster University, Hamilton, ON, Canada, 2Memorial Sloan-Kettering Cancer Center, 
New York, NY, USA, 3University of California, San Francisco, San Francisco, CA, USA
Personalized medicine (PM) targets interventions to patients who are most likely to 
beneﬁt based on genetic clinical markers or genomic information. There is little 
research on the translation of genomics into clinical practice and health policy; this 
lack of evidence on the use, effectiveness and efﬁciency of targeted technologies is a 
key challenge to their appropriate adoption and utilization. Our conceptual approach 
to translation of PM research into practice incorporates utilization, patient and pro-
vider preferences, and health economic evaluation in breast (BC) and colorectal cancer 
(CRC). We are documenting testing and treatment patterns in Canadian and US 
patients, including which patients receive testing, with which test(s) and test sequenc-
ing when conﬁrmatory testing is performed. We are also measuring patient and pro-
vider preferences with discrete choice experiments to understand choice tradeoffs for 
testing and treatment. In the third component of our research program, we are using 
decision-analytic modeling methods to evaluate the sequelae of test-treat options. This 
analytical framework will characterise the cost-effectiveness of targeted therapy to 
estimate the value of PM interventions. Using our utilisation data, we will also 
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compare guideline-adherent and routine clinical practice. Value of information analy-
sis will be employed to identify areas for future research. We are applying this trans-
lational approach to various current and developing examples of PM in cancer: 1) 
trastuzumab for human-epidermal growth factor receptor-2 positive BC; 2) gene-
expression proﬁling to identify patients who will beneﬁt most from adjuvant treatment 
in BC; 3) cytochrome P450 2D6 testing to select patients for adjuvant tamoxifen 
therapy in BC; and 4) testing for Lynch Syndrome in CRC patients and their family 
members to inform treatment and preventative interventions. This research will 
develop evidence-based information for patients, providers, industry, researchers and 
policymakers to objectively assess how PM can be beneﬁcial and efﬁcient in improving 
cancer outcomes.
PODIUM SESSION III: RESEARCH ON THE USE OF UTILITY 
MEASUREMENT
UT1
ASSOCIATION BETWEEN UTILITY AND TREATMENT AMONG 
PROSTATE CANCER PATIENTS
Jayadevappa R, Chhatre S, Malkowicz B
University of Pennsylvania, Philadelphia, PA, USA
OBJECTIVES: To analyze the association between utility, treatment and generic and 
prostate-speciﬁc health related quality of life (HRQoL) among prostate cancer 
patients. METHODS: In this longitudinal cohort study we recruited 201 (≥45 yrs) 
newly diagnosed prostate cancer patients from urology clinics of an urban academic 
hospital. Participants completed Quality of Wellbeing (QWB-SA), generic (SF-36) and 
prostate-speciﬁc (UCLA-PCI) HRQoL surveys prior to treatment and up to 24 months 
post-treatment. Clinical and demographic data were obtained via medical chart review 
and utility scores were computed using QWB-SA. To analyze the relationship between 
treatment and utility we used linear mixed effects models, after adjusting for covari-
ates. Similar models were used to examine association between generic and prostate-
speciﬁc HRQoL and utility. RESULTS: Mean baseline utility was comparable between 
radical prostatectomy (RP) and external beam radiation therapy (EBRT) groups (0.73 
vs. 0.69, p = 0.1750). Mixed effects models indicated that RP was associated with 
higher utility at 24 month (OR = 1.12, p = 0.027), after controlling for covariates. 
RP was associated with improved functioning for role physical, role emotional, vital-
ity, mental health and bodily pain and impaired urinary function. Higher scores on 
generic health subscales were indicative of higher utility. Also, for prostate-speciﬁc 
HRQoL, higher scores on bowl function, sexual function, urinary bother and bowel 
bother were associated higher utility. CONCLUSIONS: Treatment appears to have 
signiﬁcant association with post-treatment utility. Thus, utility assessment provides an 
important quantitative tool to support patient and physician clinical treatment deci-
sion making process of prostate cancer care.
UT2
COMPARISON OF HEALTH STATE UTILITY ESTIMATES IN  
COST-EFFECTIVENESS ANALYSIS
Slejko JF1, Ghushchyan VH1, Sullivan PW2
1University of Colorado Denver, Aurora, CO, USA, 2Regis University School of Pharmacy, 
Denver, CO, USA
OBJECTIVES: This study examined the effect of different utility instruments and 
tariffs on chronic condition utility scores and incremental cost-effectiveness ratios 
(ICERs). METHODS: Postponement of diabetes was modeled in a high-risk popula-
tion receiving a hypothetical intervention, as compared to a similar control group. 
Utility estimates for the general population, diabetes, hypertension, stroke, myocardial 
infarction (MI) and congestive heart failure (CHF) were taken from catalogues devel-
oped by Sullivan et al. for United States and United Kingdom EuroQOL-5D tariffs 
(EQ-5DUS and EQ-5DUK) and SF-6D, using the Medical Expenditure Panel Survey. 
Quality-adjusted life-years (QALYs) were modeled for 20 years using a 3% discount 
rate. The discounted cost of the intervention was assumed to be $150,000. RESULTS: 
The initial health state utility was lowest using the SF-6D(.709), and highest using 
EQ-5DUS(.800). The highest estimates for diabetes(.708), hypertension(.761) and 
MI(.575) were found using EQ-5DUS, but the highest stroke(.534) and CHF(.503) 
estimates were found with the SF-6D. The lowest estimates for stroke(.189), MI(.516) 
and CHF(.189) were from the EQ-5DUK, but the lowest estimates for hyperten-
sion(.583) and diabetes(.618) were from the SF-6D. The EQ-5DUK resulted in the 
largest marginal utility decrement for all conditions. The smallest decrement for 
hypertension(−.002) and diabetes(−.022) resulted from the SF-6D, but from the 
EQ-5DUS for stroke(−.069) and CHF(−.055). When these estimates were applied to 
the model, the resulting QALYs gained from the intervention were greatest from the 
EQ-5DUS(11.32) and least from the EQ-5DUK(9.77). Incremental QALYs gained 
were greatest for EQ-5DUK(3.278) and least for the SF-6D(2.880). The ICER varied 
from $46,000–$52,000 depending on the instrument/tariff. CONCLUSIONS: Differ-
ent utility instruments/tariffs resulted in unsystematic differences in chronic condition 
utilities, but the marginal decrement in each of these conditions was systematically 
lower for the EQ-5DUK and may be a trend across all conditions. Incremental QALYs 
gained differed by instrument/tariff and the ICER varied from $46,000–$52,000.
UT3
RELIABILITY OF HEALTH UTILITIES INDEX (HUI) SCORES: PATIENT 
AND PARENT INTER-RATER AGREEMENT ACROSS TWO CLINICAL 
TRIALS OF TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA 
(ALL) IN CHILDHOOD
Horsman JR1, Rae CS2, Furlong W1, Silverman LB3, Sallan SE3, Athale U2, Barr RD2
1Health Utilities Inc., Dundas, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 
3Harvard Medical School, Boston, MA, USA
OBJECTIVES: To assess differences in the reliability of HUI Mark 3 (HUI3) health-
related quality of life (HRQL) utility scores for patients between self and parent 
assessments across two Dana-Farber Cancer Institute (DFCI) clinical trials for treat-
ment of ALL during childhood. METHODS: Patients were enrolled in either the DFCI 
95-001 or 00-001trial, and were ≥12 years of age at the time of HUI survey. Patients 
and parents, blind to each other, completed HUI questionnaires at each of 5 trial 
phases: induction; CNS prophylaxis; intensiﬁcation; continuation; and post-treatment. 
Reliability was assessed in terms of inter-rater agreement of individual scores and 
differences in mean scores. Agreement was quantiﬁed using the single-measure 
two-way mixed model intra-class correlation coefﬁcient (ICC). An ICC of 0.41–0.60 
represents moderate reliability, 0.61–0.80 good reliability, and 0.81–1.00 very good 
reliability. Mean differences of >0.03 are clinically important. Statistical signiﬁcance 
was set at p < 0.05. RESULTS: The number of patient and parent paired assessments 
varied by assessment phase for both the 95-001 (minimum = 29, maximum = 50) and 
the 00-001 (minimum = 28, maximum = 54) trials. ICCs in the two trials ranged from 
0.49 (p < 0.05) to 0.88 (p < 0.05). There was substantial overlap of ICC 95% conﬁ-
dence bounds across the two trials at each of the ﬁve assessment phases. There was 
no signiﬁcant difference (p > 0.06) between patient-parent pairs of scores at any 
assessment phase in either trial. The difference between trials in mean patient-parent 
scores was ≤0.03 and insigniﬁcant (p > 0.08) for each of the 5 assessment phases. 
CONCLUSIONS: Agreement between patient and parent scores was moderate or 
better for all assessment phases in both trials. There were no important differences in 
mean patient and parent scores for any of the assessment phases of the two trials. 
Inter-rater reliability of scores was similar across the two trials. Parental assessments 
provide acceptable and consistent estimates of HRQL for children.
UT4
EVALUATING WILLINGNESS TO PAY THRESHOLDS FOR A DEMENTIA 
CAREGIVING INTERVENTION
Jutkowitz E, Gitlin L, Pizzi LT
Thomas Jefferson University, Philadelphia, PA, USA
OBJECTIVES:—Assess the methodological challenges of evaluating appropriate will-
ingness to pay thresholds (WTP) in cost-effectiveness studies which do not use a 
societal perspective or a QALY outcome measure. METHODS:—Tailored Activity 
Program (TAP), an intervention designed to reduce caregiver burden for dementia 
patients, served as a case study. Caregiver interventions such as TAP employ an 
individual perspective and non-QALY outcome measures such that standard societal 
WTP thresholds are not applicable. Two outcome measures related to caregiver 
burden were used 1) reduction in hours “on duty,” and 2) reduction in hours “doing 
things.” To estimate appropriate WTP values for each TAP outcome measure, we 
identiﬁed three studies which met these inclusion criteria: 1) published studies in the 
past 5 years using contingent valuation methodology to identify WTP, 2) assessed 
WTP for a dementia-related intervention that required an out-of-pocket expenditure, 
and 3) asked caregivers what they would be willing to pay for an outcome of reducing 
caregiver burden. We also assessed WTP based on the potential ﬁnancial savings 
caregivers could achieve from purchasing TAP. To assess proportion of time TAP was 
cost-effective, we built a Monte Carlo simulation to test the four WTP values identi-
ﬁed. RESULTS:—For the outcome measure “on duty” WTP varied between $1.06/
hr–$4.58/hr. WTP for the outcome measure “doing things” varied between $2.21/
hr–$9.57/hr. Applying WTP values to TAP indicates TAP cost-effectiveness varies 
between 50%-80% for both outcome measures. CONCLUSIONS:—If WTP data can 
not be collected prospectively or societal values can not be applied, evaluating WTP 
using comparable studies appears to be an acceptable method for informing decisions 
makers of potential cost-effectiveness. Application of WTP to TAP shows potential 
cost-effectiveness that can be expected under different WTP scenarios.
POSTER SESSION I
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Clinical  
Outcomes Methods
PMC1
EVALUATING CLINICIAN REPORTED OUTCOME (CRO) ENDPOINTS 
FOR FDA REGULATORY APPROVALS
Nixon A, Gallop K
Oxford Outcomes Ltd, Oxford, Oxon, UK
OBJECTIVES: Clinician reported outcomes (CROs) are the most commonly observed 
endpoint in FDA approved product labels (Wilke et al, 2004) but few have been 
adequately scrutinized in terms of their suitability as endpoints. This study evaluates 
four widely used CROs in order to assess their suitability as endpoints for regulatory 
approvals. METHODS: Published evidence on the Karnofsky Performance Status 
